University of Luxembourg

Alector Announces Strategic Priorities for 2025, Highlights Neurodegenerative Disease Programs

4 months ago

• Alector anticipates topline data from the Phase 3 INFRONT-3 trial of latozinemab for frontotemporal dementia with a granulin gene mutation (FTD-GRN) by Q4 2025. • Enrollment in the Phase 2 PROGRESS-AD trial of AL101/GSK4527226 for early Alzheimer's disease is expected to complete in mid-2025, with 75% of participants enrolled. • Alector is advancing its preclinical pipeline, utilizing the Alector Brain Carrier (ABC) technology to enhance therapeutic delivery for neurodegenerative diseases. • The company's cash reserves of $457.2 million as of September 30, 2024, are projected to sustain operations through 2026, supporting ongoing clinical and research programs.